epirubicin has been researched along with Colitis, Granulomatous in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (50.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Culligan, DJ; Johnston, PW; Milner, BJ; Mittal, S | 1 |
| Rieger, N; Stahl, J; Wattchow, D | 1 |
2 other study(ies) available for epirubicin and Colitis, Granulomatous
| Article | Year |
|---|---|
A case of hepatosplenic gamma-delta T-cell lymphoma with a transient response to fludarabine and alemtuzumab.
Topics: Adolescent; Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Crohn Disease; Cytarabine; Epirubicin; Epstein-Barr Virus Infections; Etoposide; Fatal Outcome; Gene Rearrangement, delta-Chain T-Cell Antigen Receptor; Gene Rearrangement, gamma-Chain T-Cell Antigen Receptor; Hematopoietic Stem Cell Transplantation; Humans; Ifosfamide; Immunosuppressive Agents; Liver; Lymphoma, T-Cell, Peripheral; Lymphoproliferative Disorders; Male; Methylprednisolone; Pentostatin; Receptors, Antigen, T-Cell, gamma-delta; Remission Induction; Spleen; Transplantation, Homologous; Vidarabine | 2006 |
Intractable Crohn's colitis and perianal disease responding to cyclophosphamide and epirubicin.
Topics: Alkylating Agents; Antibiotics, Antineoplastic; Breast Neoplasms; Carcinoma, Ductal, Breast; Chemotherapy, Adjuvant; Colitis; Crohn Disease; Cyclophosphamide; Epirubicin; Female; Humans; Immunosuppressive Agents; Mastectomy; Middle Aged; Rectal Diseases | 1997 |